GlassScriptPhysician profile
Phillip Keehan
NPI 1568146736
$3,247.78
in general payments reported to CMS, 2019-2025
20 companies · $979 in 2025
The $979 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $868 · 2024: $1,401 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,226 · Education: $21.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,226.12 |
| Education | $21.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $666.06 | 2023-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.89 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $318.52 | 2023-2025 | Acthar, Terlivaz |
| Amgen INC. | $315.97 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $312.46 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $226.04 | 2023-2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $205.63 | 2024-2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $156.15 | 2023-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $144.42 | 2023-2024 | Lupkynis |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Genzyme Corporation | $98.44 | 2023-2025 | |
| Lilly USA, LLC | $73.12 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Kyowa Kirin, INC. | $50.36 | 2025 | |
| Alnylam Pharmaceuticals INC. | $50.34 | 2024-2025 | Givlaari |
| Renalytix Ai, INC. | $48.93 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $26.22 | 2024 | |
| Novo Nordisk INC | $23.42 | 2023 | |
| Opko Pharmaceuticals, LLC | $21.66 | 2024 | Rayaldee |
| Glaxosmithkline, LLC. | $21.26 | 2025 | Shingrix |
| Ani Pharmaceuticals, INC. | $16.90 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Keehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.